Advisory Alpha’s Alexion Pharmaceuticals ALXN Stock Holding History

Advisory Alpha’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-25	Closed	-$3K	–	719
2020 Q3	$3K	Buy	+25	New	+$2.7K	﹤0.01%	595
2020 Q1	–	Sell	-25	Closed	-$2.85K	–	853
2019 Q4	$2.85K	Sell	25 -6	-19%	-$642	﹤0.01%	638
2019 Q3	$2.94K	Buy	+31	New	+$3.49K	﹤0.01%	604
2019 Q2	–	Sell	-3	Closed	-$395	–	711
2019 Q1	$395	Buy	+3	New	+$373	﹤0.01%	693

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Advisory Alpha's ALXN Position: Q4 2020 in Review

Advisory Alpha sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 25 shares — an estimated $3K sold.

Advisory Alpha first reported a position in ALXN in Q1 2019 and held it in 4 quarters. The position peaked at $3K in Q3 2020. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Advisory Alpha reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Advisory Alpha sold 25 Alexion Pharmaceuticals shares in Q4 2020, an estimated $3K.
Advisory Alpha first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Advisory Alpha's Alexion Pharmaceuticals position peaked at $3K in Q3 2020.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Advisory Alpha's 13F filing for Q4 2020, filed 16 Feb 2021.